Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The aim of this study was to determine the feasibility of using bacteriophage therapeutics in spinal epidural abscess (SEA) by reviewing the causes and outcomes of SEA at a single institution and testing a bacteriophage for activity against preserved SEA clinical isolates. Materials and Methods: Medical records were reviewed of patients that received incision and drainage for SEA at a single medical center. Causative organisms, incidence of coinciding bacteremia and outcomes were recorded. A subset of SEA patients (N = 11), that had preserved clinical isolates, were assessed to evaluate if a bacteriophage therapeutic had ample activity to those isolates as seen with spot tests and growth inhibition assays. Results: Staphylococcus aureus was the predominate bacterial cause (71%) and bacteremia was associated with 96% of S. aureus SEA. Over 50% of the patients either died within three months, had recurrence of their infection, required repeat debridement, or had long term sequalae. A single bacteriophage had positive spot tests for all the S. aureus clinical isolates and inhibited bacterial growth for more than 24 hours for 9 of the 11 (82%) clinical isolates. Conclusion: SEA is associated with significant mortality and morbidity making this a potential indication for adjuvant bacteriophage therapeutics. Since S. aureus is the predominate cause of SEA and most cases are associated bacteremia this creates a potential screening and treatment platform for Staphylococcal bacteriophages therapeutics, allowing for potential pilot studies to be devised.
Abstract
Background: The aim of this study was to determine the feasibility of using bacteriophage therapeutics in spinal epidural abscess (SEA) by reviewing the causes and outcomes of SEA at a single institution and testing a bacteriophage for activity against preserved SEA clinical isolates. Materials and Methods: Medical records were reviewed of patients that received incision and drainage for SEA at a single medical center. Causative organisms, incidence of coinciding bacteremia and outcomes were recorded. A subset of SEA patients (N = 11), that had preserved clinical isolates, were assessed to evaluate if a bacteriophage therapeutic had ample activity to those isolates as seen with spot tests and growth inhibition assays. Results: Staphylococcus aureus was the predominate bacterial cause (71%) and bacteremia was associated with 96% of S. aureus SEA. Over 50% of the patients either died within three months, had recurrence of their infection, required repeat debridement, or had long term sequalae. A single bacteriophage had positive spot tests for all the S. aureus clinical isolates and inhibited bacterial growth for more than 24 hours for 9 of the 11 (82%) clinical isolates. Conclusion: SEA is associated with significant mortality and morbidity making this a potential indication for adjuvant bacteriophage therapeutics. Since S. aureus is the predominate cause of SEA and most cases are associated bacteremia this creates a potential screening and treatment platform for Staphylococcal bacteriophages therapeutics, allowing for potential pilot studies to be devised.
참고문헌 (25)
- Schwab JH, "Spinal epidural abscess : diagnosis, management, and outcomes", J Am Acad Orthop Surg, 28, pp.e929~38 (2020)
- Baker AS, "Spinal epidural abscess", N Engl J Med, 293, pp.463~468 (1975)
- Darouiche RO, "Spinal epidural abscess", N Engl J Med, 355, pp.2012~2020 (2006)
- Shah AA, "Development of predictive algorithms for pre-treatment motor deficit and 90-day mortality in spinal epidural abscess", J Bone Joint Surg Am, 100, pp.1030~1038 (2018)
- Connor DE Jr, "Comparison of operative and nonoperative management of spinal epidural abscess : a retrospective review of clinical and laboratory predictors of neurological outcome", J Neurosurg Spine, 19, pp.119~127 (2013)
- Löhr M, "Spinal epidural abscess : prognostic factors and comparison of different surgical treatment strategies", Acta Neurochir(Wien), 147, pp.159~166 (2005)
- Doub JB, "Potential use of adjuvant bacteriophage therapy with debridement, antibiotics, and implant retention surgery to treat chronic prosthetic joint infections", Open Forum Infect Dis, 8, pp.ofab277~ (2021)
- Suh GA, "Considerations for the use of phage therapy in clinical practice", Antimicrob Agents Chemother, 66, pp.e0207121~ (2022)
- Doub JB, "Experience using adjuvant bacteriophage therapy for the treatment of 10 recalcitrant periprosthetic joint infections : a case series", Clin Infect Dis, 76, pp.e1463~6 (2023)
- de Mesy Bentley KL, "Evidence of Staphylococcus aureus deformation, proliferation, and migration in canaliculi of live cortical bone in murine models of osteomyelitis", J Bone Miner Res, 32, pp.985~990 (2017)
- Wang X, "Involvement of small colony variant-related heme biosynthesis genes in Staphylococcus aureus persister formation in vitro", Front Microbiol, 12, pp.756809~ (2021)
- Plumet L, "Bacteriophage therapy for Staphylococcus aureus infections : a review of animal models, treatments, and clinical trials", Front Cell Infect Microbiol, 12, pp.907314~ (2022)
- Capparelli R, "Experimental phage therapy against Staphylococcus aureus in mice", Antimicrob Agents Chemother, 51, pp.2765~2773 (2007)
- Kaur S, "In vivo assessment of phage and linezolid based implant coatings for treatment of methicillin resistant S. aureus(MRSA)mediated orthopaedic device related infections", PLoS One, 11, pp.e0157626~ (2016)
- Doub JB, "Bacteriophage therapy for periprosthetic joint infections : current limitations and research needed to advance this therapeutic", J Orthop Res, 41, pp.1097~1104 (2023)
- Tuchman A, "The indications and timing for operative management of spinal epidural abscess : literature review and treatment algorithm", Neurosurg Focus, 37, pp.E8~ (2014)
- DePalma BJ, "Assessment of staphylococcal clinical isolates from periprosthetic joint infections for potential bacteriophage therapy", J Bone Joint Surg Am, 104, pp.693~699 (2022)
- Totten KMC, "Phage activity against planktonic and biofilm Staphylococcus aureus periprosthetic joint infection isolates", Antimicrob Agents Chemother, 66, pp.e0187921~ (2022)
- Doub JB, "Impact of bacterial phenotypic variation with bacteriophage therapy : a pilot study with prosthetic joint infection isolates", Int J Infect Dis, 119, pp.44~46 (2022)
- Azam AH, "Peculiarities of Staphylococcus aureus phages and their possible application in phage therapy", Appl Microbiol Biotechnol, 103, pp.4279~4289 (2019)
- Patel AR, "Spinal epidural abscesses : risk factors, medical versus surgical management, a retrospective review of 128 cases", Spine J, 14, pp.326~330 (2014)
- Arko L 4th, "Medical and surgical management of spinal epidural abscess : a systematic review", Neurosurg Focus, 37, pp.E4~ (2014)
- Patel AR, "Spinal epidural abscesses : risk factors, medical versus surgical management, a retrospective review of 128 cases", Spine J, 14, pp.326~330 (2014)
- Cano EJ, "Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection : case report and in vitro characterization of anti-biofilm activity", Clin Infect Dis, 73, pp.e144~51 (2021)
- Schooley RT, "Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection", Antimicrob Agents Chemother, 61, pp.e00954-17~ (2017)